Apolipoprotein e gene polymorphism and risk for coronary heart disease in the chinese population: A meta-analysis of 61 studies including 6634 cases and 6393 controls

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Zhang, Ming Duo ^a,b   Gu, Wei ^c   Qiao, Shi Bin ^d   Zhu, En Jun ^a,b   Zhao, Quan Ming ^a,b   Lv, Shu Zheng ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF HEART   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d PEOPLE S HOSPITAL OF RIZHAO   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4;

ALLELE; APOLIPOPROTEIN E GENE; APOLIPOPROTEIN E2 GENE; APOLIPOPROTEIN E3 GENE; APOLIPOPROTEIN E4 GENE; ARTICLE; CARDIOVASCULAR RISK; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); POPULATION BASED CASE CONTROL STUDY; POPULATION GENETICS; RISK ASSESSMENT; SYSTEMATIC REVIEW; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; CHINA; CORONARY ARTERY DISEASE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; PUBLISHING; RISK; RISK FACTOR;

APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; CORONARY ARTERY DISEASE; CORONARY DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ODDS RATIO; POLYMORPHISM, GENETIC; PUBLICATION BIAS; RISK FACTORS;

EID: 84899678935     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095463     Document Type: Article

References (36)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. (2013) Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127: e6-e245.
2. Kullo IJ, Ding K (2007) Mechanisms of disease: The genetic basis of coronary heart disease. Nat Clin Pract Cardiovasc Med 4: 558-569. (Pubitemid 47490763)
3. Mi X, Eskridge KM, George V, Wang D (2011) Structural equation modeling of gene-environment interactions in coronary heart disease. Ann Hum Genet 75: 255-265.
4. Talmud PJ (2007) Gene-environment interaction and its impact on coronary heart disease risk. Nutr Metab Cardiovasc Dis 17: 148-152.
5. Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, et al. (2011) Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 43: 333-338.
6. Mahley RW, Rall SC Jr (2000) Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1: 507-537.
7. Greenow K, Pearce N, Ramji D (2005) The key role of apolipoprotein E in atherosclerosis. Journal of Molecular Medicine 83: 329-342. (Pubitemid 41201798)
8. Utermann G, Hees M, Steinmetz A (1977) Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature 269: 604-607.
9. Hallman DM, Boerwinkle E, Saha N, Sandholzer C, Menzel HJ, et al. (1991) The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet 49: 338-349. (Pubitemid 21891679)
10. Hatters DM, Peters-Libeu CA, Weisgraber KH (2006) Apolipoprotein E structure: insights into function. Trends Biochem Sci 31: 445-454. (Pubitemid 44108662)
11. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, et al. (1994) Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 272: 1666-1671. (Pubitemid 24359137)
12. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, et al. (2007) Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 298: 1300-1311. (Pubitemid 47443344)
13. Song YQ, Stampfer MJ, Liu SM (2004) Meta-analysis: Apolipoprotein E genotypes and risk for coronary heart disease. Annals of Internal Medicine 141: 137-147. (Pubitemid 38937836)
14. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6: e1000097.
15. Woolf B (1955) On estimating the relation between blood group and disease. Ann Hum Genet 19: 251-253.
16. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10: 101-129.
17. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558. (Pubitemid 34746062)
18. Anthopoulos PG, Hamodrakas SJ, Bagos PG (2010) Apolipoprotein E polymorphisms and type 2 diabetes: a meta-analysis of 30 studies including 5423 cases and 8197 controls. Mol Genet Metab 100: 283-291.
19. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
20. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. (Pubitemid 27387172)
21. Mahley RW (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240: 622-630.
22. Kuusi T, Nieminen MS, Ehnholm C, Yki-Jarvinen H, Valle M, et al. (1989) Apoprotein E polymorphism and coronary artery disease. Increased prevalence of apolipoprotein E-4 in angiographically verified coronary patients. Arteriosclerosis 9: 237-241. (Pubitemid 19092108)
23. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, et al. (2002) Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 155: 487-495. (Pubitemid 34208040)
24. Davignon J, Gregg RE, Sing CF (1988) Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8: 1-21. (Pubitemid 18049171)
25. Raber J, Huang Y, Ashford JW (2004) ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging 25: 641-650. (Pubitemid 38686487)
26. Dergunov AD (2011) Apolipoprotein E genotype as a most significant predictor of lipid response at lipid-lowering therapy: mechanistic and clinical studies. Biomed Pharmacother 65: 597-603.
27. Khan TA, Shah T, Prieto D, Zhang W, Price J, et al. (2013) Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals. Int J Epidemiol 42: 475-492.
28. Anoop S, Misra A, Meena K, Luthra K (2010) Apolipoprotein E polymorphism in cerebrovascular & coronary heart diseases. Indian J Med Res 132: 363-378.
29. Yamada N, Shimano H, Yazaki Y (1995) Role of apolipoprotein E in lipoprotein metabolism and in the process of atherosclerosis. J Atheroscler Thromb 2 Suppl 1: S29-33.
30. Grammer TB, Hoffmann MM, Renner W, Kleber ME, Winkelmann BR, et al. (2011) Apolipoprotein E genotypes, circulating C-reactive protein and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study. Atherosclerosis 215: 487-493.
31. Gungor Z, Anuurad E, Enkhmaa B, Zhang W, Kim K, et al. (2012) Apo E4 and lipoprotein-associated phospholipase A2 synergistically increase cardiovascular risk. Atherosclerosis 223: 230-234.
32. Colton CA, Brown CM, Vitek MP (2005) Sex steroids, APOE genotype and the innate immune system. Neurobiol Aging 26: 363-372. (Pubitemid 40082720)
33. Brown CM, Wright E, Colton CA, Sullivan PM, Laskowitz DT, et al. (2002) Apolipoprotein E isoform mediated regulation of nitric oxide release. Free Radic Biol Med 32: 1071-1075. (Pubitemid 34603344)
34. Yin YW, Sun QQ, Zhang BB, Hu AM, Liu HL, et al. (2013) Association between Apolipoprotein E Gene Polymorphism and the Risk of Coronary Artery Disease in Chinese Population: Evidence from a Meta-Analysis of 40 Studies. PLoS One 8: e66924.
35. Grimes DA, Schulz KF (2002) Bias and causal associations in observational research. Lancet 359: 248-252. (Pubitemid 34113828)
36. Little J, Bradley L, Bray MS, Clyne M, Dorman J, et al. (2002) Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 156: 300-310. (Pubitemid 34857997)